Company Overview of Nurel Therapeutics, Inc.
Nurel Therapeutics, Inc., a biotechnology company, develops products to treat and manage pain and peripheral nerve damage. Its gene-based therapeutic product, NPE1, delivers enkephalin directly to the peripheral nerve cells and reduces pain in animal models. The company’s drug delivery technology is a gene-based therapy that selectively targets neurons for the treatment of chronic pain due to diabetes, spinal cord injuries, and cancer. Nurel was founded in 2003 and is based in Pittsburgh, Pennsylvania. As of December 16, 2005, Nurel Therapeutics, Inc. is a subsidiary of Mertiva AB (publ).
100 Technology Drive
Pittsburgh, PA 15219
Founded in 2003
Key Executives for Nurel Therapeutics, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Nurel Therapeutics, Inc., please visit www.nureltx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.